Get the Stockscreener App
1.43
1.38%
-0.02
After Hours:
1.43
Actinium Pharmaceuticals Inc stock is traded at $1.43, with a volume of 125.64K.
It is down -1.38% in the last 24 hours and up +0.00% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.45
Open:
$1.42
24h Volume:
125.64K
Relative Volume:
0.57
Market Cap:
$44.61M
Revenue:
$81,000
Net Income/Loss:
$-41.04M
P/E Ratio:
-1.0859
EPS:
-1.3169
Net Cash Flow:
$-30.69M
1W Performance:
+1.42%
1M Performance:
+0.00%
6M Performance:
-0.69%
1Y Performance:
+0.00%
1-Day Range:
$1.402
$1.49
1-Week Range:
$1.33
$1.49
52-Week Range:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.43 | 45.23M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance
Published on: 2025-12-20 18:07:18 - Улправда
Will Actinium Pharmaceuticals Inc. stock benefit from upcoming earnings reportsForecast Cut & Short-Term High Return Ideas - Улправда
Will Actinium Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Patterns & Growth Oriented Trade Recommendations - Улправда
AstraZeneca’s Long-Term Isotope Deal Validates Actinium Pharmaceuticals’ Core Technology - AD HOC NEWS
Can Actinium Pharmaceuticals Inc. stock continue upward trendEarnings Growth Report & Expert Curated Trade Setups - Улправда
Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Growth vs Value & Reliable Breakout Stock Forecasts - Улправда
How Actinium Pharmaceuticals Inc. (Delaware) stock responds to job market shiftsJuly 2025 Closing Moves & High Accuracy Buy Signal Tips - Улправда
Can Actinium Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 Catalysts & Consistent Profit Trade Alerts - DonanımHaber
Aug Intraday: Can Actinium Pharmaceuticals Inc. stock continue upward trendJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Is Actinium Pharmaceuticals Inc. stock a top pick in earnings seasonJuly 2025 PostEarnings & Growth Oriented Trade Recommendations - Улправда
Published on: 2025-12-18 21:38:16 - Улправда
Can Actinium Pharmaceuticals Inc. (Delaware) stock sustain revenue momentumInsider Buying & AI Forecasted Stock Moves - Улправда
Actinium Pharmaceuticals stock rises after promising breast cancer therapy data - Investing.com Australia
Why Is Actinium Pharmaceuticals Stock Rising Today? - Menafn.com
Why is Actinium Pharmaceuticals stock rising today? - MSN
Actinium (ATNM) Reveals Promising Preclinical Data for Novel Can - GuruFocus
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia - openPR.com
Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why - Defense World
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins - openPR.com
Actinium Pharmaceuticals: Clinical Milestone and Promising Data Fuel Oncology Pipeline - AD HOC NEWS
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances - openPR.com
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer - marketscreener.com
ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa - openPR.com
Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa - openPR.com
Can Actinium Pharmaceuticals Inc. (7AY1) stock double in coming yearsJuly 2025 Opening Moves & Safe Entry Point Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock gain from lower interest ratesJuly 2025 Highlights & Risk Controlled Stock Alerts - Newser
Why analysts recommend Actinium Pharmaceuticals Inc. (Delaware) stock2025 Earnings Surprises & Daily Entry Point Trade Alerts - Newser
How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international markets2025 Short Interest & Real-Time Chart Pattern Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock beat Nasdaq index returnsChart Signals & Consistent Profit Alerts - Newser
Why hedge funds are buying Actinium Pharmaceuticals Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Why Actinium Pharmaceuticals Inc. stock is a value investor pick2025 Market WrapUp & Expert Approved Trade Ideas - Newser
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily
Will Actinium Pharmaceuticals Inc. stock benefit from green energy trendsJobs Report & Daily Entry Point Alerts - Newser
Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser
How Actinium Pharmaceuticals Inc. (7AY1) stock valuation compares with sectorQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
How cyclical is Actinium Pharmaceuticals Inc. (7AY1) stock compared to rivalsJuly 2025 Volume & Smart Investment Allocation Insights - Newser
Actinium’s ATNM-400 shows efficacy in resistant breast cancers By Investing.com - Investing.com Australia
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Da - GuruFocus
Actinium's ATNM-400 shows strong efficacy in TNBC, beats therapy resistance at SABCS - marketscreener.com
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):